Abstract | OBJECTIVE: METHODS: This post hoc subgroup analysis of data pooled from two 3-week, randomized, placebo- and olanzapine-controlled trials (December 2004-April 2006, N = 489 and November 2004-April 2006, N = 488) examined a subgroup of patients meeting criteria for moderate-to-severe mixed major depressive episodes, defined using DSM-IV-TR criteria for mixed episodes ( mania and major depression simultaneously) with a baseline Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥ 20. RESULTS: Decreases in MADRS scores (least squares mean [SE]), the a priori primary outcome, were significantly greater in the asenapine group than in the placebo group from baseline to day 7 (-11.02 [1.82] vs -4.78 [1.89]; P = .0195), day 21 (-14.03 [2.01] vs -7.43 [2.09]; P = .0264), and endpoint (-10.71 [1.76] vs -5.19 [1.98]; P = .039). Decreases in MADRS scores with asenapine were significantly greater than with olanzapine from baseline to day 7 (-6.26 [1.47]; P = .0436). Decreases in Young Mania Rating Scale mean total score were greater with asenapine than with placebo or olanzapine at all time points assessed. A significantly greater reduction from baseline to day 21 in the Short Form-36 mental component summary score was observed with asenapine, but not olanzapine, compared with placebo (16.57 vs 5.97; P = .0093). Asenapine was generally well tolerated. CONCLUSIONS: These data provide support for the potential efficacy of asenapine in mixed major depressive episodes; however, these data cannot be linearly extrapolated to nonmixed major depression.
|
Authors | Michael Berk, John W G Tiller, Jun Zhao, Lakshmi N Yatham, Gin S Malhi, Emmanuelle Weiller |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 76
Issue 6
Pg. 728-34
(Jun 2015)
ISSN: 1555-2101 [Electronic] United States |
PMID | 25612216
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © Copyright 2015 Physicians Postgraduate Press, Inc. |
Chemical References |
- Antipsychotic Agents
- Dibenzocycloheptenes
- Heterocyclic Compounds, 4 or More Rings
- Benzodiazepines
- asenapine
- Olanzapine
|
Topics |
- Adult
- Aged
- Analysis of Variance
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Benzodiazepines
(adverse effects, therapeutic use)
- Bipolar Disorder
(complications, drug therapy)
- Depressive Disorder, Major
(complications, drug therapy)
- Dibenzocycloheptenes
- Double-Blind Method
- Female
- Heterocyclic Compounds, 4 or More Rings
(adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Multicenter Studies as Topic
- Olanzapine
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Treatment Outcome
- Young Adult
|